GSK3528869
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 19
Of
19
Go to page
1
October 16, 2025
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=174 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed
Trial completion • Hepatitis B • Infectious Disease • Inflammation
April 04, 2025
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=174 | Active, not recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Feb 2026 ➔ Jun 2025 | Trial primary completion date: Feb 2026 ➔ Jun 2025
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
November 29, 2024
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
(clinicaltrials.gov)
- P1/2 | N=135 | Terminated | Sponsor: GlaxoSmithKline | Trial completion date: Oct 2025 ➔ Oct 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Oct 2024; Following the primary phase(24 weeks post last vaccination)the predefined efficacy endpoint was not met.Noting the lack of efficacy and with the objective to prioritize patients'safety GSK has decided on the early termination of the study.
Trial completion date • Trial primary completion date • Trial termination • Viral vector • Hepatitis B • Hepatology • Infectious Disease • Inflammation
January 18, 2024
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
(clinicaltrials.gov)
- P1 | N=148 | Active, not recruiting | Sponsor: GlaxoSmithKline | Phase classification: P1/2 ➔ P1 | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025
Phase classification • Trial completion date • Trial primary completion date • Viral vector • Hepatitis B • Hepatology • Infectious Disease • Inflammation
June 08, 2023
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=184 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
June 08, 2023
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
(clinicaltrials.gov)
- P1/2 | N=148 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting
Enrollment closed • Viral vector • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
January 25, 2023
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=184 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Jan 2026
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
October 27, 2022
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=184 | Recruiting | Sponsor: GlaxoSmithKline | Trial primary completion date: Mar 2023 ➔ Oct 2025
Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
October 21, 2022
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
(clinicaltrials.gov)
- P1/2 | N=148 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Dec 2024 ➔ Jul 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
June 29, 2022
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=184 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Trial primary completion date: Aug 2024 ➔ Mar 2023
Enrollment open • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
March 11, 2022
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
(clinicaltrials.gov)
- P2 | N=184 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
December 09, 2021
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
(clinicaltrials.gov)
- P1/2; N=148; Recruiting; Sponsor: GlaxoSmithKline; Phase classification: P1 ➔ P1/2
Clinical • Phase classification • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
May 28, 2021
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Aug 2024 ➔ Jan 2025; Trial primary completion date: Aug 2024 ➔ Jan 2025
Clinical • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8
March 23, 2020
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Sep 2023 ➔ Jul 2024; Trial primary completion date: Sep 2023 ➔ Jul 2024
Clinical • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
December 12, 2019
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Recruiting; Sponsor: GlaxoSmithKline; Trial completion date: May 2023 ➔ Sep 2023; Trial primary completion date: May 2023 ➔ Sep 2023
Clinical • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
July 24, 2020
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Recruiting; Sponsor: GlaxoSmithKline; Suspended ➔ Recruiting
Clinical • Enrollment open • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
May 21, 2019
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
March 07, 2019
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Not yet recruiting; Sponsor: GlaxoSmithKline
Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
April 13, 2020
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
(clinicaltrials.gov)
- P1; N=148; Suspended; Sponsor: GlaxoSmithKline; Recruiting ➔ Suspended
Clinical • Trial suspension • Hepatitis B • Hepatology • Infectious Disease • CD4 • CD8
1 to 19
Of
19
Go to page
1